aripiprazole accord healthcare 10 mg tabletki
accord healthcare polska sp. z o.o. - aripiprazolum - tabletki - 10 mg
aripiprazole accord healthcare 15 mg tabletki
accord healthcare polska sp. z o.o. - aripiprazolum - tabletki - 15 mg
aripiprazole accord healthcare 10 mg tabletki ulegające rozpadowi w jamie ustnej
accord healthcare polska sp. z o.o. - aripiprazolum - tabletki ulegające rozpadowi w jamie ustnej - 10 mg
aripiprazole accord healthcare 15 mg tabletki ulegające rozpadowi w jamie ustnej
accord healthcare polska sp. z o.o. - aripiprazolum - tabletki ulegające rozpadowi w jamie ustnej - 15 mg
amoksycylina global vet health 500 mg/g proszek do podania w wodzie do picia
global vet health s.l. - amoxicillinum trihydricum - proszek do podania w wodzie do picia - 500 mg/g - indyk; kaczka; kura; świnia
allergodil sprint 1,5 mg/ml aerozol do nosa, roztwór
mylan healthcare sp. z o.o. - azelastini hydrochloridum - aerozol do nosa, roztwór - 1,5 mg/ml
astepro 1,5 mg/ml aerozol do nosa, roztwór
mylan healthcare sp. z o.o. - azelastini hydrochloridum - aerozol do nosa, roztwór - 1,5 mg/ml
humira
abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - leki immunosupresyjne - zapoznaj się z dokumentem z informacjami o produkcie.
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - blokada nerwowo-mięśniowa - wszystkie inne produkty terapeutyczne - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
lacosamide adroiq
extrovis eu ltd. - lakozamid - padaczka - przeciwpadaczkowe narzędzia, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.